<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37112883</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Characterization of Anti-Poliovirus Compounds Isolated from Edible Plants.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">903</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15040903</ELocationID><Abstract><AbstractText>Poliovirus (PV) is the causative agent of poliomyelitis and is a target of the global eradication programs of the World Health Organization (WHO). After eradication of type 2 and 3 wild-type PVs, vaccine-derived PV remains a substantial threat against the eradication as well as type 1 wild-type PV. Antivirals could serve as an effective means to suppress the outbreak; however, no anti-PV drugs have been approved at present. Here, we screened for effective anti-PV compounds in a library of edible plant extracts (a total of 6032 extracts). We found anti-PV activity in the extracts of seven different plant species. We isolated chrysophanol and vanicoside B (VCB) as the identities of the anti-PV activities of the extracts of <i>Rheum rhaponticum</i> and <i>Fallopia sachalinensis</i>, respectively. VCB targeted the host PI4KB/OSBP pathway for its anti-PV activity (EC<sub>50</sub> = 9.2 μM) with an inhibitory effect on in vitro PI4KB activity (IC<sub>50</sub> = 5.0 μM). This work offers new insights into the anti-PV activity in edible plants that may serve as potent antivirals for PV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arita</LastName><ForeName>Minetaro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3314-6626</Identifier><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi 208-0011, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6302-4507</Identifier><AffiliationInfo><Affiliation>Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition, 1-2 Hachimandai, Tsukuba 305-0843, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000715307">Fallopia sachalinensis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D010945" MajorTopicYN="N">Plants, Edible</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PI4KB</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">edible plant</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">picornavirus</Keyword><Keyword MajorTopicYN="N">virus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>1</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37112883</ArticleId><ArticleId IdType="pmc">PMC10145814</ArticleId><ArticleId IdType="doi">10.3390/v15040903</ArticleId><ArticleId IdType="pii">v15040903</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kitamura N., Semler B.L., Rothberg P.G., Larsen G.R., Adler C.J., Dorner A.J., Emini E.A., Hanecak R., Lee J.J., van der Werf S., et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981;291:547–553. doi: 10.1038/291547a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/291547a0</ArticleId><ArticleId IdType="pubmed">6264310</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G.R., O’Reilly K.M., Grassly N.C., Edmunds W.J., Mach O., Santhana Gopala Krishnan R., Voorman A., Vertefeuille J.F., Abdelwahab J., Gumede N., et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401–405. doi: 10.1126/science.aba1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO.  [(accessed on 27 February 2023)].  Available online:  https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/</Citation></Reference><Reference><Citation>Link-Gelles R., Lutterloh E., Schnabel Ruppert P., Backenson P.B., St George K., Rosenberg E.S., Anderson B.J., Fuschino M., Popowich M., Punjabi C., et al. Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater—New York, June-August 2022. MMWR Morb. Mortal Wkly. Rep. 2022;71:1065–1068. doi: 10.15585/mmwr.mm7133e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7133e2</ArticleId><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Klapsa D., Wilton T., Zealand A., Bujaki E., Saxentoff E., Troman C., Shaw A.G., Tedcastle A., Majumdar M., Mate R., et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet. 2022;400:1531–1538. doi: 10.1016/S0140-6736(22)01804-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01804-9</ArticleId><ArticleId IdType="pmc">PMC9627700</ArticleId><ArticleId IdType="pubmed">36243024</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis E., Kopel E., Singer S.R., Kaliner E., Moerman L., Moran-Gilad J., Sofer D., Manor Y., Shulman L.M., Mendelson E., et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Eurosurveillance. 2013;18:20586. doi: 10.2807/1560-7917.ES2013.18.38.20586.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2013.18.38.20586</ArticleId><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., Weiner A.J., Bandyopadhyay A.S., Van Damme P., De Coster I., et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020;27:736–751.e8. doi: 10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay A.S., Zipursky S. A novel tool to eradicate an ancient scourge: The novel oral polio vaccine type 2 story. Lancet Infect. Dis. 2023;23:e67–e71. doi: 10.1016/S1473-3099(22)00582-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00582-5</ArticleId><ArticleId IdType="pubmed">36162417</ArticleId></ArticleIdList></Reference><Reference><Citation>Collett M.S., Neyts J., Modlin J.F. A case for developing antiviral drugs against polio. Antiviral Res. 2008;79:179–187. doi: 10.1016/j.antiviral.2008.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.04.002</ArticleId><ArticleId IdType="pubmed">18513807</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication, National Research Council . Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. The National Academies Press; Washington, DC, USA: 2006.</Citation></Reference><Reference><Citation>De Palma A.M., Vliegen I., De Clercq E., Neyts J. Selective inhibitors of picornavirus replication. Med. Res. Rev. 2008;28:823–884. doi: 10.1002/med.20125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20125</ArticleId><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynell L.A., Kirkegaard K., Klymkowsky M.W. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 1992;66:1985–1994. doi: 10.1128/jvi.66.4.1985-1994.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.66.4.1985-1994.1992</ArticleId><ArticleId IdType="pmc">PMC288987</ArticleId><ArticleId IdType="pubmed">1312615</ArticleId></ArticleIdList></Reference><Reference><Citation>Irurzun A., Perez L., Carrasco L. Involvement of membrane traffic in the replication of poliovirus genomes: Effects of brefeldin A. Virology. 1992;191:166–175. doi: 10.1016/0042-6822(92)90178-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(92)90178-R</ArticleId><ArticleId IdType="pubmed">1329315</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordeleau M.E., Mori A., Oberer M., Lindqvist L., Chard L.S., Higa T., Belsham G.J., Wagner G., Tanaka J., Pelletier J. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2006;2:213–220. doi: 10.1038/nchembio776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio776</ArticleId><ArticleId IdType="pubmed">16532013</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller R., Vignuzzi M., Andino R., Frydman J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 2007;21:195–205. doi: 10.1101/gad.1505307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1505307</ArticleId><ArticleId IdType="pmc">PMC1770902</ArticleId><ArticleId IdType="pubmed">17234885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H.H., Kunz A., Simon V.A., Palese P., Shaw M.L. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc. Natl. Acad. Sci. USA. 2011;108:5777–5782. doi: 10.1073/pnas.1101143108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1101143108</ArticleId><ArticleId IdType="pmc">PMC3078400</ArticleId><ArticleId IdType="pubmed">21436031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K., Kim D.E., Jang K.S., Kim S.J., Cho S., Kim C. Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion. Oncotarget. 2017;8:115315–115325. doi: 10.18632/oncotarget.23258.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.23258</ArticleId><ArticleId IdType="pmc">PMC5777774</ArticleId><ArticleId IdType="pubmed">29383162</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Yang E., Hu C., Cheng H., Chen C.Y., Huang D., Wang R., Zhao Y., Rong L., Vignuzzi M., et al. Cell-Based High-Throughput Screening Assay Identifies 2′,2′-Difluoro-2′-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent. ACS Infect. Dis. 2017;3:45–53. doi: 10.1021/acsinfecdis.6b00116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.6b00116</ArticleId><ArticleId IdType="pmc">PMC5754216</ArticleId><ArticleId IdType="pubmed">27733043</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollman A.P. Inhibitors of protein biosynthesis. V. Effects of emetine on protein and nucleic acid biosynthesis in HeLa cells. J. Biol. Chem. 1968;243:4089–4094. doi: 10.1016/S0021-9258(18)93283-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)93283-7</ArticleId><ArticleId IdType="pubmed">4299101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikel J.H., Paget C.J., DeLong D.C., Nelson J.D., Wu C.Y., Paschal J.W., Dinner A., Templeton R.J., Chaney M.O., Jones N.D., et al. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J. Med. Chem. 1980;23:368–372. doi: 10.1021/jm00178a004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00178a004</ArticleId><ArticleId IdType="pubmed">6247489</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz B.A., Vance L.M. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 1995;69:4189–4197. doi: 10.1128/jvi.69.7.4189-4197.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.7.4189-4197.1995</ArticleId><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu N.Y., Ilnytska O., Belov G., Santiana M., Chen Y.H., Takvorian P.M., Pau C., van der Schaar H., Kaushik-Basu N., Balla T., et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141:799–811. doi: 10.1016/j.cell.2010.03.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.03.050</ArticleId><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 2011;85:2364–2372. doi: 10.1128/JVI.02249-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02249-10</ArticleId><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Delang L., Paeshuyse J., Neyts J. The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem. Pharmacol. 2012;84:1400–1408. doi: 10.1016/j.bcp.2012.07.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2012.07.034</ArticleId><ArticleId IdType="pmc">PMC7111036</ArticleId><ArticleId IdType="pubmed">22885339</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod A.M., Mitchell D.R., Palmer N.J., Van de Poel H., Conrath K., Andrews M., Leyssen P., Neyts J. Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. ACS Med. Chem. Lett. 2013;4:585–589. doi: 10.1021/ml400095m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ml400095m</ArticleId><ArticleId IdType="pmc">PMC4030314</ArticleId><ArticleId IdType="pubmed">24900715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejdrova I., Chalupska D., Kogler M., Sala M., Plackova P., Baumlova A., Hrebabecky H., Prochazkova E., Dejmek M., Guillon R., et al. Highly Selective Phosphatidylinositol 4-Kinase IIIbeta Inhibitors and Structural Insight into Their Mode of Action. J. Med. Chem. 2015;58:3767–3793. doi: 10.1021/acs.jmedchem.5b00499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b00499</ArticleId><ArticleId IdType="pubmed">25897704</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Dobrikov G., Purstinger G., Galabov A.S. Allosteric Regulation of Phosphatidylinositol 4-Kinase III Beta by an Antipicornavirus Compound MDL-860. ACS Infect. Dis. 2017;3:585–594. doi: 10.1021/acsinfecdis.7b00053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.7b00053</ArticleId><ArticleId IdType="pubmed">28605587</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M., Thibaut H.J., van der Linden L., Lanke K., Heggermont W., Ireland S., Andrews R., Arimilli M., Altel T., De Clercq E., et al. Mutations in the non-structural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 2009;53:1850–1857. doi: 10.1128/AAC.00934-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00934-08</ArticleId><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Takebe Y., Wakita T., Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and early stage of enterovirus 71 infection. J. Gen. Virol. 2010;91:2734–2744. doi: 10.1099/vir.0.023374-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.023374-0</ArticleId><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J. Virol. 2013;87:4252–4260. doi: 10.1128/JVI.03546-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03546-12</ArticleId><ArticleId IdType="pmc">PMC3624399</ArticleId><ArticleId IdType="pubmed">23365445</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating J.R., van der Linden L., Albulescu L., Bigay J., Arita M., Delang L., Leyssen P., van der Schaar H.M., Lanke K.H., Thibaut H.J., et al. Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein. Cell Rep. 2015;10:600–615. doi: 10.1016/j.celrep.2014.12.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.054</ArticleId><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Albulescu L., Bigay J., Biswas B., Weber-Boyvat M., Dorobantu C.M., Delang L., van der Schaar H.M., Jung Y.S., Neyts J., Olkkonen V.M., et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017;140:37–44. doi: 10.1016/j.antiviral.2017.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.01.008</ArticleId><ArticleId IdType="pubmed">28088354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R., Shih S.R. An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 1999;341:929–935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuffenecker I., Mirand A., Josset L., Henquell C., Hecquet D., Pilorge L., Petitjean-Lecherbonnier J., Manoha C., Legoff J., Deback C., et al. Epidemiological and clinical characteristics of patients infected with enterovirus D68, France, July to December 2014. Eurosurveillance. 2016;21:30226. doi: 10.2807/1560-7917.ES.2016.21.19.30226.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.19.30226</ArticleId><ArticleId IdType="pubmed">27195770</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Fuchino H., Kawakami H., Ezaki M., Kawahara N. Characterization of a New Antienterovirus D68 Compound Purified from Avocado. ACS Infect. Dis. 2020;6:2291–2300. doi: 10.1021/acsinfecdis.0c00404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00404</ArticleId><ArticleId IdType="pubmed">32567833</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Bigay J. Poliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III beta/Oxysterol-Binding Protein Family I Pathway. ACS Infect. Dis. 2019;5:962–973. doi: 10.1021/acsinfecdis.9b00038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00038</ArticleId><ArticleId IdType="pubmed">30919621</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Nagata N., Sata T., Miyamura T., Shimizu H. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. Pt 11J. Gen. Virol. 2006;87:3317–3327. doi: 10.1099/vir.0.82172-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.82172-0</ArticleId><ArticleId IdType="pubmed">17030866</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltera R.F., Jr., Tershak D.R. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J. Virol. 1989;63:4441–4444. doi: 10.1128/jvi.63.10.4441-4444.1989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.63.10.4441-4444.1989</ArticleId><ArticleId IdType="pmc">PMC251066</ArticleId><ArticleId IdType="pubmed">2550675</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S., Saleh M.C., Gitlin L., Beske O., Andino R. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J. Virol. 2004;78:3378–3386. doi: 10.1128/JVI.78.7.3378-3386.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.7.3378-3386.2004</ArticleId><ArticleId IdType="pmc">PMC371039</ArticleId><ArticleId IdType="pubmed">15016860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner E.J., Liu H.M., Oberste M.S., Pallansch M., Collett M.S., Kirkegaard K. Dominant drug targets suppress the emergence of antiviral resistance. eLife. 2014;3:e03830. doi: 10.7554/eLife.03830.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.03830</ArticleId><ArticleId IdType="pmc">PMC4270081</ArticleId><ArticleId IdType="pubmed">25365453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser A.G., Sgro J.Y., Rueckert R.R. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J. Virol. 1994;68:8193–8201. doi: 10.1128/jvi.68.12.8193-8201.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.68.12.8193-8201.1994</ArticleId><ArticleId IdType="pmc">PMC237285</ArticleId><ArticleId IdType="pubmed">7966611</ArticleId></ArticleIdList></Reference><Reference><Citation>Purstinger G., De Palma A.M., Zimmerhofer G., Huber S., Ladurner S., Neyts J. Synthesis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzonitriles. Bioorg. Med. Chem. Lett. 2008;18:5123–5125. doi: 10.1016/j.bmcl.2008.07.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.07.099</ArticleId><ArticleId IdType="pubmed">18710805</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. Pt 10J. Gen. Virol. 2008;89:2518–2530. doi: 10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Meselhy M.R. Inhibition of LPS-induced NO production by the oleogum resin of Commiphora wightii and its constituents. Phytochemistry. 2003;62:213–218. doi: 10.1016/S0031-9422(02)00388-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0031-9422(02)00388-6</ArticleId><ArticleId IdType="pubmed">12482459</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias D.A., Urban S. Phytochemical investigation of the Australian lichens Ramalina glaucescens and Xanthoria parietina. Nat. Prod. Commun. 2009;4:959–964. doi: 10.1177/1934578X0900400717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1934578X0900400717</ArticleId><ArticleId IdType="pubmed">19731602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.S., Lee B.W., Kim M.R., Jun J.G. Syntheses of Resveratrol and its Hydroxylated Derivatives as Radical Scavenger and Tyrosinase Inhibitor. Bull. Korean Chem. Soc. 2010;31:971–975. doi: 10.5012/bkcs.2010.31.04.971.</Citation><ArticleIdList><ArticleId IdType="doi">10.5012/bkcs.2010.31.04.971</ArticleId></ArticleIdList></Reference><Reference><Citation>Commodari F., Khiat A., Ibrahimi S., Brizius A.R., Kalkstein N. Comparison of the phytoestrogen trans-resveratrol (3,4′,5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn. Reson. Chem. 2005;43:567–572. doi: 10.1002/mrc.1583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrc.1583</ArticleId><ArticleId IdType="pubmed">15809979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo I., Murai Y., Soediro I., Soetarno S., Sastrodihardjo S. Cytotoxic anthraquinones from Rheum pulmatum. Phytochemistry. 1992;31:1063–1065. doi: 10.1016/0031-9422(92)80078-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0031-9422(92)80078-S</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L.-M., Tang J., Li H.-L., Shen Y.-H., Peng C.-Y., Zhang W.-D. A new stilbene glycoside from the n-butanol fraction of Veratrum dahuricum. Chem. Nat. Compd. 2009;45:325–329. doi: 10.1007/s10600-009-9352-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10600-009-9352-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngoc T.M., Hung T.M., Thuong P.T., Na M., Kim H., Ha D.T., Min B.-S., Minh P.T.H., Bae K. Inhibition of Human Low Density Lipoprotein and High Density Lipoprotein Oxidation by Oligostilbenes from Rhubarb. Biol. Pharm. Bull. 2008;31:1809–1812. doi: 10.1248/bpb.31.1809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.31.1809</ArticleId><ArticleId IdType="pubmed">18758083</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezet R., Perret C., Jean-Denis J.B., Tabacchi R., Gindro K., Viret O. Delta-viniferin, a resveratrol dehydrodimer: One of the major stilbenes synthesized by stressed grapevine leaves. J. Agric. Food Chem. 2003;51:5488–5492. doi: 10.1021/jf030227o.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf030227o</ArticleId><ArticleId IdType="pubmed">12926902</ArticleId></ArticleIdList></Reference><Reference><Citation>Semple S.J., Pyke S.M., Reynolds G.D., Flower R.L. In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus. Antiviral Res. 2001;49:169–178. doi: 10.1016/S0166-3542(01)00125-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-3542(01)00125-5</ArticleId><ArticleId IdType="pubmed">11428243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiem P.V., Nhiem N.X., Cuong N.X., Hoa T.Q., Huong H.T., Huong L.M., Minh C.V., Kim Y.H. New phenylpropanoid esters of sucrose from Polygonum hydropiper and their antioxidant activity. Arch. Pharm. Res. 2008;31:1477–1482. doi: 10.1007/s12272-001-2133-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-001-2133-y</ArticleId><ArticleId IdType="pubmed">19023545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgway N.D., Dawson P.A., Ho Y.K., Brown M.S., Goldstein J.L. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. J. Cell Biol. 1992;116:307–319. doi: 10.1083/jcb.116.2.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.116.2.307</ArticleId><ArticleId IdType="pmc">PMC2289278</ArticleId><ArticleId IdType="pubmed">1730758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi J., Arita M., Sakai S., Kojima H., Senda M., Senda T., Hanada K., Kato R. Ligand Recognition by the Lipid Transfer Domain of Human OSBP Is Important for Enterovirus Replication. ACS Infect. Dis. 2022;8:1161–1170. doi: 10.1021/acsinfecdis.2c00108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.2c00108</ArticleId><ArticleId IdType="pubmed">35613096</ArticleId></ArticleIdList></Reference><Reference><Citation>Torney H.L., Dulworth J.K., Steward D.L. Antiviral activity and mechanism of action of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) Antimicrob. Agents Chemother. 1982;22:635–638. doi: 10.1128/AAC.22.4.635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.22.4.635</ArticleId><ArticleId IdType="pmc">PMC183805</ArticleId><ArticleId IdType="pubmed">7181474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishitsuka H., Ohsawa C., Ohiwa T., Umeda I., Suhara Y. Antipicornavirus flavone Ro 09-0179. Antimicrob. Agents Chemother. 1982;22:611–616. doi: 10.1128/AAC.22.4.611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.22.4.611</ArticleId><ArticleId IdType="pmc">PMC183801</ArticleId><ArticleId IdType="pubmed">6295260</ArticleId></ArticleIdList></Reference><Reference><Citation>Galabov A.S., Nikolaeva L., Philipov S. Aporphinoid alkaloid glaucinone: A selective inhibitor of poliovirus replication. Antiviral. Res. 1995;26((Suppl. 1)):A347. doi: 10.1016/0166-3542(95)94930-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(95)94930-Z</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaeva-Glomb L., Philipov S., Galabov A.S. Oxoglaucin—Enterovirus replication inhibitor: Study on the antiviral spectrum, mode of action and development of resistance (in Bulgarian) J. Bulg. Acad. Sci. 2007;120:22–26.</Citation></Reference><Reference><Citation>Wang J., Zhang T., Du J., Cui S., Yang F., Jin Q. Anti-enterovirus 71 effects of chrysin and its phosphate ester. PLoS ONE. 2014;9:e89668. doi: 10.1371/journal.pone.0089668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089668</ArticleId><ArticleId IdType="pmc">PMC3943725</ArticleId><ArticleId IdType="pubmed">24598537</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunaseelan S., Wong K.Z., Min N., Sun J., Ismail N., Tan Y.J., Lee R.C.H., Chu J.J.H. Prunin suppresses viral IRES activity and is a potential candidate for treating enterovirus A71 infection. Sci. Transl. Med. 2019;11:eaar5759. doi: 10.1126/scitranslmed.aar5759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aar5759</ArticleId><ArticleId IdType="pubmed">31666401</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H.M., Wang F., Qiu Y., Ye X., Hanson P., Shen H., Yang D. Emodin inhibits coxsackievirus B3 replication via multiple signalling cascades leading to suppression of translation. Biochem. J. 2016;473:473–485. doi: 10.1042/BJ20150419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20150419</ArticleId><ArticleId IdType="pubmed">26621875</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong T., Zhang L.Y., Wang Z.Y., Wang Y., Song F.M., Zhang Y.H., Yu J.H. Rheum emodin inhibits enterovirus 71 viral replication and affects the host cell cycle environment. Acta Pharmacol. Sin. 2017;38:392–401. doi: 10.1038/aps.2016.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2016.110</ArticleId><ArticleId IdType="pmc">PMC5342659</ArticleId><ArticleId IdType="pubmed">27840410</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent C.I., Johnson K.L., Sarnow P., Kirkegaard K. Functional coupling between replication and packaging of poliovirus replicon RNA. J. Virol. 1999;73:427–435. doi: 10.1128/JVI.73.1.427-435.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.1.427-435.1999</ArticleId><ArticleId IdType="pmc">PMC103849</ArticleId><ArticleId IdType="pubmed">9847348</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. High-Order Epistasis and Functional Coupling of Infection Steps Drive Virus Evolution toward Independence from a Host Pathway. Microbiol. Spectr. 2021;9:e0080021. doi: 10.1128/Spectrum.00800-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00800-21</ArticleId><ArticleId IdType="pmc">PMC8557862</ArticleId><ArticleId IdType="pubmed">34468191</ArticleId></ArticleIdList></Reference><Reference><Citation>Buontempo P.J., Cox S., Wright-Minogue J., DeMartino J.L., Skelton A.M., Ferrari E., Albin R., Rozhon E.J., Girijavallabhan V., Modlin J.F., et al. SCH 48973: A potent, broad-spectrum, antienterovirus compound. Antimicrob. Agents Chemother. 1997;41:1220–1225. doi: 10.1128/AAC.41.6.1220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.41.6.1220</ArticleId><ArticleId IdType="pmc">PMC163890</ArticleId><ArticleId IdType="pubmed">9174174</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Moore D., Anderson B., Pallansch M.A., Pevear D.C., Collett M.S. In vitro antiviral activity of V-073 against polioviruses. Antimicrob. Agents Chemother. 2009;53:4501–4503. doi: 10.1128/AAC.00671-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00671-09</ArticleId><ArticleId IdType="pmc">PMC2764203</ArticleId><ArticleId IdType="pubmed">19635956</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., Petersen A., Smith G.J., 3rd, Zalman L.S., Burns-Naas L.A., et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2005;49:2267–2275. doi: 10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden E., Liu H.M., Wang-Chern S.W., Oberste M.S. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res. 2013;98:186–191. doi: 10.1016/j.antiviral.2013.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.03.003</ArticleId><ArticleId IdType="pubmed">23499651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankam M.K., Burns J.M., Collett M.S., Corrado M.L., Hincks J.R. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers. Antimicrob. Agents Chemother. 2021;65:e0102921. doi: 10.1128/AAC.01029-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01029-21</ArticleId><ArticleId IdType="pmc">PMC8448163</ArticleId><ArticleId IdType="pubmed">34370575</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay M.A., Collett M.S., Hincks J.R., Oberste M.S., Pallansch M.A., Okayasu H., Sutter R.W., Modlin J.F., Dowdle W.R. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J. Infect. Dis. 2014;210((Suppl. 1)):S447–S453. doi: 10.1093/infdis/jiu043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu043</ArticleId><ArticleId IdType="pubmed">25316866</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO.  [(accessed on 27 February 2023)].  Available online:  https://polioeradication.org/tools-and-library/current-research-areas/antivirals/</Citation></Reference><Reference><Citation>Zimmermann M.L., Sneden A.T. Vanicosides A and B, protein kinase C inhibitors from Polygonum pensylvanicum. J. Nat. Prod. 1994;57:236–242. doi: 10.1021/np50104a007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np50104a007</ArticleId><ArticleId IdType="pubmed">8176400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad R., Sahidin I., Taher M., Low C., Noor N.M., Sillapachaiyaporn C., Chuchawankul S., Sarachana T., Tencomnao T., Iskandar F., et al. Polygonumins A, a newly isolated compound from the stem of Polygonum minus Huds with potential medicinal activities. Sci. Rep. 2018;8:4202. doi: 10.1038/s41598-018-22485-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22485-5</ArticleId><ArticleId IdType="pmc">PMC5845017</ArticleId><ArticleId IdType="pubmed">29523802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawrot-Hadzik I., Zmudzinski M., Matkowski A., Preissner R., Kesik-Brodacka M., Hadzik J., Drag M., Abel R. Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors-Molecular Docking and In Vitro Study. Pharmaceuticals. 2021;14:742. doi: 10.3390/ph14080742.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14080742</ArticleId><ArticleId IdType="pmc">PMC8399519</ArticleId><ArticleId IdType="pubmed">34451839</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure. Microbiol. Immunol. 2014;58:239–256. doi: 10.1111/1348-0421.12144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1348-0421.12144</ArticleId><ArticleId IdType="pubmed">24527995</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III β Inhibitor. ACS Infect. Dis. 2016;2:140–148. doi: 10.1021/acsinfecdis.5b00122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.5b00122</ArticleId><ArticleId IdType="pubmed">27624965</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyoo H., Dorobantu C.M., van der Schaar H.M., van Kuppeveld F.J.M. Modulation of proteolytic polyprotein processing by coxsackievirus mutants resistant to inhibitors targeting phosphatidylinositol-4-kinase IIIbeta or oxysterol binding protein. Antiviral Res. 2017;147:86–90. doi: 10.1016/j.antiviral.2017.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.10.006</ArticleId><ArticleId IdType="pubmed">29024767</ArticleId></ArticleIdList></Reference><Reference><Citation>Melia C.E., van der Schaar H.M., Lyoo H., Limpens R., Feng Q., Wahedi M., Overheul G.J., van Rij R.P., Snijder E.J., Koster A.J., et al. Escaping Host Factor PI4KB Inhibition: Enterovirus Genomic RNA Replication in the Absence of Replication Organelles. Cell Rep. 2017;21:587–599. doi: 10.1016/j.celrep.2017.09.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.068</ArticleId><ArticleId IdType="pmc">PMC5656745</ArticleId><ArticleId IdType="pubmed">29045829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarche M.J., Borawski J., Bose A., Capacci-Daniel C., Colvin R., Dennehy M., Ding J., Dobler M., Drumm J., Gaither L.A., et al. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 2012;56:5149–5156. doi: 10.1128/AAC.00946-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00946-12</ArticleId><ArticleId IdType="pmc">PMC3457382</ArticleId><ArticleId IdType="pubmed">22825118</ArticleId></ArticleIdList></Reference><Reference><Citation>Spickler C., Lippens J., Laberge M.K., Desmeules S., Bellavance E., Garneau M., Guo T., Hucke O., Leyssen P., Neyts J., et al. Phosphatidylinositol 4-Kinase III Beta Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal Phenotype In Vivo. Antimicrob. Agents Chemother. 2013;57:3358–3368. doi: 10.1128/AAC.00303-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00303-13</ArticleId><ArticleId IdType="pmc">PMC3697394</ArticleId><ArticleId IdType="pubmed">23650168</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui T., Fujita M., Ishibashi Y., Nomanbhoy T., Rosenblum J.S., Nagasawa M. 134. KRP-A218, an Orally Active and Selective PI4KB Inhibitor with Broad-Spectrum Anti-Rhinovirus Activity, Has Potent Therapeutic Antiviral Activity In Vivo. Open Forum Infect. Dis. 2021;8((Suppl. 1)):S82. doi: 10.1093/ofid/ofab466.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab466.134</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733–747. doi: 10.1016/j.cell.2006.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.03.035</ArticleId><ArticleId IdType="pmc">PMC2946820</ArticleId><ArticleId IdType="pubmed">16647110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>